此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

肾病综合征研究网 (NEPTUNE)

2026年11月5日 更新者:Matthias Kretzler、University of Michigan

罕见病临床研究网下的肾病综合征研究网

Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD) cases (2005) at an annual cost in the US of more than $3 billion. However, the clinical classification of these diseases is widely believed to be inadequate by the scientific community. Given the poor understanding of MCD/FSGS and MN biology, it is not surprising that the available therapies are imperfect. The therapies lack a clear biological basis, and as many families have experienced, they are often not beneficial, and in fact may be significantly toxic. Given these observations, it is essential that research be conducted that address these serious obstacles to effectively caring for patients.

In response to a request for applications by the National Institutes of Health, Office of Rare Diseases (NIH, ORD) for the creation of Rare Disease Clinical Research Consortia, a number of affiliated universities joined together with The NephCure Foundation the NIDDK, the ORDR, and the University of Michigan in collaboration towards the establishment of a Nephrotic Syndrome (NS) Rare Diseases Clinical Research Consortium.

Through this consortium the investigators hope to understand the fundamental biology of these rare diseases and aim to bank long-term observational data and corresponding biological specimens for researchers to access and further enrich.

研究概览

详细说明

Idiopathic Nephrotic Syndrome (NS) is a rare disease syndrome responsible for approximately 12% of all causes of end-stage kidney disease (ESRD) and up to 20% of ESRD in children. Treatment strategies for Focal and Segmental Glomerulosclerosis (FSGS), Minimal Change Disease (MCD) and Membranous Nephropathy (MN), the major causes of NS, include high dose prolonged steroid therapy, cyclophosphamide, cyclosporine A, tacrolimus, mycophenolate mofetil and other immunosuppressive agents, which all carry significant side effects. Failure to obtain remission using the current treatment approaches frequently results in progression to ESRD with its associated costs, morbidities, and mortality. In the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry, half of the pediatric patients with Steroid Resistant Nephrotic Syndrome required renal replacement therapy within two years of being enrolled in the disease registry. FSGS also has a high recurrence rate following kidney transplantation (30-40%) and is the most common recurrent disease leading to allograft loss.

The prevailing classification of Nephrotic Syndrome categorizes patients into FSGS, MCD, and MN, if in the absence of other underlying causes, glomerular histology shows a specific histological pattern. This classification does not adequately predict the heterogeneous natural history of patients with FSGS, MCD, and MN. Major advances in understanding the pathogenesis of FSGS and MCD have come over the last ten years from the identification of several mutated genes responsible for causing Steroid Resistant Nephrotic Syndrome (SRNS) presenting with FSGS or MCD histopathology in humans and model organisms. These functionally distinct genetic disorders can present with indistinguishable FSGS lesions on histology confirming the presence of heterogeneous pathogenic mechanisms under the current histological diagnoses.

The limited understanding of FSGS, MCD, and MN biology in humans has necessitated a descriptive classification system in which heterogeneous disorders are grouped together. This invariably consigns these heterogeneous patients to the same therapeutic approaches, which use blunt immunosuppressive drugs that lack a clear biological basis, are often not beneficial, and are complicated by significant toxicity. The foregoing shortcomings make a strong case that concerted and innovative investigational strategies combining basic science, translational, and clinical methods should be employed to study FSGS, MCD, and MN. It is for these reasons that the Nephrotic Syndrome Study Network is established to conduct clinical and translational research in patients with FSGS/MCD and MN.

研究类型

观察性的

注册 (估计的)

1200

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Ontario
      • Richmond Hill、Ontario、加拿大、L4C 4Z3
        • 完全的
        • York Central Hospital
      • Scarborough Village、Ontario、加拿大、M1H 3G4
        • 完全的
        • Scarborough Hospital
      • Toronto、Ontario、加拿大、M4N 3M5
        • 招聘中
        • Sunnybrook Hospital
        • 首席研究员:
          • Michelle Hladunewich, MD
        • 接触:
      • Toronto、Ontario、加拿大、L5M 2N1
        • 招聘中
        • Credit Valley Hospital
        • 副研究员:
          • Phillip Boll, MD
        • 接触:
      • Toronto、Ontario、加拿大、M5G2C4
        • 招聘中
        • University Health Network
        • 接触:
        • 接触:
        • 首席研究员:
          • Daniel Cattran, MD
        • 副研究员:
          • Heather Reich, MD
        • 副研究员:
          • Michelle Hladunewich, MD
    • California
      • Los Angeles、California、美国、90227
        • 招聘中
        • University of Southern California-Children's Hospital
        • 首席研究员:
          • Kevin Lemley, MD, PhD
        • 接触:
      • Palo Alto、California、美国、94304
        • 招聘中
        • Stanford University School of Medicine
        • 接触:
        • 首席研究员:
          • Richard Lafayette, MD
      • San Francisco、California、美国、94158
        • 尚未招聘
        • University of California San Francisco Benioff Children's Hospitals
        • 首席研究员:
          • Paul Brakeman, MD, PhD
        • 接触:
      • Torrance、California、美国、90502
        • 招聘中
        • Lundquist Biomedical Research Institute at Harbor UCLA Medical Center
        • 接触:
        • 首席研究员:
          • Sharon Adler, MD
    • Colorado
      • Aurora、Colorado、美国、80045
      • Aurora、Colorado、美国、80045
        • 尚未招聘
        • University of Colorado Anschutz School of Medicine
        • 首席研究员:
          • Amber Podoll, MD
        • 接触:
    • Florida
      • Miami、Florida、美国、33136
        • 招聘中
        • University of Miami Miller School of Medicine
        • 接触:
        • 首席研究员:
          • Alessia Fornoni, MD. PhD
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory University and Children's Healthcare of Atlanta
        • 首席研究员:
          • Laurence Greenbaum, MD, PhD
        • 接触:
    • Illinois
      • Chicago、Illinois、美国、60680
        • 招聘中
        • John Stroger Cook County Hospital
        • 接触:
        • 首席研究员:
          • Ambarish Athavale, MD
    • Kansas
      • Kansas City、Kansas、美国、66160
        • 招聘中
        • University of Kansas Medical Center
        • 接触:
        • 首席研究员:
          • Ellen McCarthy, MD
    • Maryland
      • Baltimore、Maryland、美国、21287
        • 招聘中
        • Johns Hopkins Medical Institute
        • 接触:
        • 首席研究员:
          • Alicia Neu, MD
        • 副研究员:
          • Michael Choi, MD
      • Bethesda、Maryland、美国、20892
        • 完全的
        • Kidney Disease Section, NIDDK, NIH
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • University of Michigan Medical Center
        • 接触:
        • 首席研究员:
          • Matthias Kretzler, MD
        • 接触:
          • Amanda Williams, BS - adult
          • 电话号码:734-615-5017
          • 邮箱:amwi@umich.edu
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • CS Mott Children's Hospital, University of Michigan
        • 副研究员:
          • Debbie Gipson, MD, MS
        • 接触:
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • 完全的
        • Mayo Clinic
    • Missouri
      • Kansas City、Missouri、美国、64108
        • 招聘中
        • Children's Mercy Hospital
        • 首席研究员:
          • Tarak Srivastava, MD
        • 接触:
      • St Louis、Missouri、美国、63110
        • 尚未招聘
        • Washington University - St Louis
        • 接触:
        • 首席研究员:
          • Vikas Dharnidharka, MD, PhD
    • New York
      • New Hyde Park、New York、美国、11040
        • 招聘中
        • Cohen Children's Hospital
        • 首席研究员:
          • Christine Sethna, MD
        • 接触:
      • New York、New York、美国、10032
        • 招聘中
        • Columbia University Medical Center
        • 首席研究员:
          • Andrew Bomback, MD, MPH
        • 接触:
      • New York、New York、美国、10010
        • 招聘中
        • New York University Medical Center
        • 接触:
        • 首席研究员:
          • Olga Zhadnova, MD
        • 首席研究员:
          • Howard Trachtman, MD
        • 接触:
      • New York、New York、美国、10016
        • 招聘中
        • Bellevue Hospital
        • 接触:
        • 首席研究员:
          • Laura Barisoni, MD
        • 副研究员:
          • Olga Zhadnova, MD
      • New York、New York、美国、10016
        • 招聘中
        • New York University Veterans Administration
        • 接触:
        • 首席研究员:
          • Laura Barisoni, MD
        • 副研究员:
          • Olga Zhadnova, MD
      • The Bronx、New York、美国、11040
        • 招聘中
        • Montefiore Medical Center
        • 接触:
        • 副研究员:
          • Robert Woroniecki, MD
        • 首席研究员:
          • Frederick Kaskel, MD
    • North Carolina
      • Chapel Hill、North Carolina、美国、27599
        • 招聘中
        • University of North Carolina at Chapel Hill
        • 接触:
        • 首席研究员:
          • Patrick H. Nachman, MD
        • 副研究员:
          • Susan L. Hogan, PhD, MPH
        • 副研究员:
          • Keisha Gibson, MD
        • 接触:
      • Charlotte、North Carolina、美国、28203
        • 招聘中
        • Atrium Health Levine Children's Hospital
        • 首席研究员:
          • Susan Massengill, MD
        • 接触:
      • Winston-Salem、North Carolina、美国、27157
        • 撤销
        • Wake Forest School of Medicine
    • Ohio
      • Cleveland、Ohio、美国、44195
        • 招聘中
        • Cleveland Clinic
        • 副研究员:
          • Katherine Dell, MD
        • 接触:
        • 接触:
          • Villarreal
      • Cleveland、Ohio、美国、44106
        • 完全的
        • University Hospital Rainbow Babies & Children's Hospital
      • Cleveland、Ohio、美国、44109
        • 完全的
        • MetroHealth Hospital at Case Western Medical Center
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University Wexner Medical Center
        • 接触:
        • 首席研究员:
          • Salem Almaani, MD
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • University of Pennsylvania
        • 接触:
        • 首席研究员:
          • Lawrence Holzman, MD
        • 接触:
      • Philadelphia、Pennsylvania、美国、19104
        • 招聘中
        • Children's Hospital of Philadelphia
        • 副研究员:
          • Kevin Meyers, MD
        • 接触:
      • Philadelphia、Pennsylvania、美国、19140
        • 招聘中
        • Temple University
        • 接触:
        • 首席研究员:
          • Crystal Gadegbeku, MD
        • 首席研究员:
          • Iris Lee, MD
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina
        • 首席研究员:
          • David Selewski, MD, MS
    • Texas
      • Dallas、Texas、美国、75390
      • Houston、Texas、美国、77030
        • 招聘中
        • Texas Children's Hospital - Baylor College of Medicine
        • 接触:
        • 首席研究员:
          • Shweta S. Shah, MD
    • Washington
      • Seattle、Washington、美国、98195
      • Seattle、Washington、美国、98145
      • Spokane、Washington、美国、99204

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

不超过 80年 (孩子、成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Patients with signs and symptoms of kidney disease consistent with FSGS, MCD, MN or proteinuric renal disease or pediatric participants not previously biopsied, who present for patient care at participating clinical centers will be eligible for Cohort A (biopsy cohort) study population targeted for enrollment into the NEPTUNE study.

To establish a cohort of pediatric participants with incident nephrotic syndrome, Cohort B, a non-biopsy cohort has been initiated for Protocol V4.0. This population, <19 years of age, presenting for nephrotic syndrome and less than 30 days of immunosuppression therapy exposure, will also be targeted for enrollment into the cNEPTUNE study.

Potential participants willing to receive their initial care and subsequent follow-up study visits at one of these sites are welcome to participate.

描述

Cohort A (biopsy cohort) Inclusion Criteria:

Patients presenting with an incipient clinical diagnosis for FSGS/MCD or MN or pediatric participants not previously biopsied, with a clinical diagnosis for FSGS/MCD or MN meeting the following inclusion criteria:

  • Documented urinary protein excretion ≥1500 mg/24 hours or spot protein: creatinine ratio equivalent at the time of diagnosis or within 3 months of the screening/eligibility visit.
  • Scheduled renal biopsy

Cohort B (non-biopsy, cNEPTUNE) Inclusion Criteria:

  • Age <19 years of age

  • Initial presentation with <30 days immunosuppression therapy

  • Proteinuria/nephrotic

    • UA>2+ and edema OR
    • UA>2+ and serum albumin <3 OR
    • UPC > 2g/g and serum albumin <3

Exclusion Criteria (Cohort A&B):

  • Prior solid organ transplant
  • A clinical diagnosis of glomerulopathy without diagnostic renal biopsy
  • Clinical, serological or histological evidence of systemic lupus erythematosus (SLE) as defined by the ARA criteria. Patients with membranous in combination with SLE will be excluded because this entity is well defined within the International Society of Nephrology/Renal Pathology Society categories of lupus nephritis, and frequently overlaps with other classification categories of SLE nephritis (68)
  • Clinical or histological evidence of other renal diseases (Alport, Nail Patella, Diabetic Nephropathy, IgA-nephritis, monoclonal gammopathy (multiple myelomas), genito-urinary malformations with vesico-urethral reflux or renal dysplasia)
  • Known systemic disease diagnosis at time of enrollment with a life expectancy less than 6 months
  • Unwillingness or inability to give a comprehensive informed consent
  • Unwillingness to comply with study procedures and visit schedule
  • Institutionalized individuals (e.g., prisoners)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
干预/治疗
FSGS/MCD Cohort (Cohort A)

Focal Segmental Glomerulosclerosis/Minimal Change Disease (FSGS/MCD) Cohort

Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for FSGS or MCD.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

MN Cohort (Cohort A)

Membranous Nephropathy (MN) Cohort

Participants enrolled in NEPTUNE with a biopsy proven histological diagnosis for MN.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

Other glomerulopathies cohort

Participants enrolled in NEPTUNE and determined to not have FSGS/MCD or MN will be followed in a third group.

Eligible participants must be scheduled for a clinically indicated renal biopsy.

Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.

cNEPTUNE (Cohort B)

Participants < 19 years of age, with < 30 days exposure to immunosuppression therapy who are not scheduled for renal biopsy.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Event rate of change in urinary protein excretion and renal function.
大体时间:60 months

Defined as remission, partial remission and non-remission

60 months
Rate of change in renal function.
大体时间:60 months

Defined as:

  1. 25 mls/min/1.73m2 reduction in follow-up estimated GFR (using the 4-variable MDRD equation for ages ≥18 years and modified Schwartz for ages <18 years) compared to baseline estimated GFR
  2. 50% decline in follow-up estimated GFR compared to baseline measurement
  3. End stage renal disease defined as estimated GFR ≤10cc/min, initiation of maintenance dialysis or preemptive kidney transplantation.
60 months

次要结果测量

结果测量
措施说明
大体时间
Quality of Life:
大体时间:60 months

Patient-reported outcome will be assessed using Quality of Life questionnaires at regular intervals as stipulated in the visit calendar using the SF-36, PedsQL and the Patient Reported Outcome Measurement Information System (PROMIS) (in the age-appropriate groups).

60 months
Malignancies
大体时间:60 months

Any cancer diagnosis of the skin, hematopoietic system, or solid organ after enrollment in NEPTUNE

60 months
Infections, Serious and Systemic
大体时间:60 months

Infections including one of the following:

  1. Documented diagnosis of infection of the skin or subcutaneous tissue (e.g. cellulitis), vascular system, peritoneum, or any vital organ requiring the use of parenteral antibiotics and/or oral antibiotics alone or in combination for a treatment interval of ≥72 hours.
  2. Hospitalization for treatment of infection
60 months
Thromboembolic Events
大体时间:60 months

Documented diagnosis of one of the following:

  1. Embolic cerebrovascular accident
  2. Deep venous thrombosis
  3. Renal vein thrombosis or
  4. Pulmonary embolus
60 months
Hospitalization
大体时间:60 months

Documented hospital admission, including observation for ≥24 hours.

60 months
Emergency Department/ Observation Unit Visit
大体时间:60 months

Documented visit to an emergency department or observation unit that does not lead to hospitalization and is less than 24 hours.

60 months
Acute Kidney Injury
大体时间:60 months

Documented diagnosis of acute kidney injury as defined by the AKIN (Mehta et al., Critical Care 2007, 11:R31) and/or renal failure requiring renal replacement therapy <3 months.

60 months
Death
大体时间:60 months
  1. Documentation of death that is secondary to infection or sepsis.
  2. Cardiovascular/Cerebrovascular-related Death: Sudden death; Myocardial infarction; Congestive heart failure; Primary intractable serious arrhythmia; Peripheral vascular disease; Ischemic cerebrovascular accident; Hemorrhagic cerebrovascular accident; Thromboembolic event
  3. Documentation of death secondary to cancer
  4. Other Death: Documentation of death that does not fall into the above categories.
60 months
New Onset Diabetes
大体时间:60 months

Diagnosis of diabetes as indicated by 1 or more of the following not present at NEPTUNE Enrollment:

  1. Documented diagnosis of diabetes in medical record
  2. Casual (non-fasting) blood glucose > 200 mg/dL c) Fasting blood glucose > 126 mg/dL d) 2 hour glucose > 200 after oral glucose tolerance test e) chronic use (>6 mos) hypoglycemic therapy outside of pregnancy f) Hemogloblin A1C >= 6.5%
60 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Matthias Kretzler, MD、University of Michigan

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2010年4月1日

初级完成 (估计的)

2030年12月31日

研究完成 (估计的)

2030年12月31日

研究注册日期

首次提交

2010年7月29日

首先提交符合 QC 标准的

2010年9月23日

首次发布 (估计的)

2010年9月24日

研究记录更新

最后更新发布 (实际的)

2026年11月10日

上次提交的符合 QC 标准的更新

2026年11月5日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅